CU24626B1 - Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana - Google Patents

Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana

Info

Publication number
CU24626B1
CU24626B1 CU2019000113A CU20190113A CU24626B1 CU 24626 B1 CU24626 B1 CU 24626B1 CU 2019000113 A CU2019000113 A CU 2019000113A CU 20190113 A CU20190113 A CU 20190113A CU 24626 B1 CU24626 B1 CU 24626B1
Authority
CU
Cuba
Prior art keywords
proteins
inflammatory
pharmaceutical composition
peptides
composition based
Prior art date
Application number
CU2019000113A
Other languages
English (en)
Other versions
CU20190113A7 (es
Inventor
Crespo Nashelly Esquivel
Hernández Yenela García
Raveiro Yanary Govin
Verdecia Mayelín Odelín
Martínez Yoel Perea
Capiro Rachel Rabago
Zamora Mary Carmen Reyes
Martínez Claudio Rodríguez
Oramas Diana Rosa Viera
Original Assignee
Centro Nac De Biopreparados
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Nac De Biopreparados filed Critical Centro Nac De Biopreparados
Priority to CU2019000113A priority Critical patent/CU24626B1/es
Priority to PCT/CU2020/050006 priority patent/WO2021129897A1/es
Priority to EP20904540.0A priority patent/EP4129318A4/en
Priority to CN202080097527.4A priority patent/CN115209908A/zh
Priority to MX2022007991A priority patent/MX2022007991A/es
Priority to CA3165245A priority patent/CA3165245A1/en
Publication of CU20190113A7 publication Critical patent/CU20190113A7/es
Publication of CU24626B1 publication Critical patent/CU24626B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/32—Thymopoietins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención consiste en una composición farmacéutica basada en proteínas y péptidos que las componen con una concentración total de proteínas de 0,2 a 3 mg/ml o mg/g. Las proteínas y péptidos son combinados seleccionando una o varios pertenecientes al menos a dos grupos clasificados por su actividad sobre el organismo humano, entre ellas actividad antioxidante, sobre el sistema ubiquitino-proteosoma, antiinflamatoria y moduladora del sistema inmune, antimicrobiana y sobre la transcripción y síntesis de proteínas. A partir de la combinación de proteínas y péptidos se conforma una composición farmacéutica para su administración por vía intranasal, intramuscular, endovenosa, oral o sublingual para el tratamiento de enfermedades del sistema nervioso central y periférico, autoinmunes e inflamatorias, infecciosas, inmunodeficiencias primarias y secundarias y cáncer.</p>
CU2019000113A 2019-12-26 2019-12-26 Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana CU24626B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CU2019000113A CU24626B1 (es) 2019-12-26 2019-12-26 Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana
PCT/CU2020/050006 WO2021129897A1 (es) 2019-12-26 2020-11-23 Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoría y antimicrobiana
EP20904540.0A EP4129318A4 (en) 2019-12-26 2020-11-23 Protein-based pharmaceutical composition with neuroprotective, immunomodulating, anti-inflammatory and antimicrobial activity
CN202080097527.4A CN115209908A (zh) 2019-12-26 2020-11-23 具有神经保护、免疫调节、抗炎和抗微生物活性的基于蛋白质的药学组合物
MX2022007991A MX2022007991A (es) 2019-12-26 2020-11-23 Composicion farmaceutica a base de proteinas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana.
CA3165245A CA3165245A1 (en) 2019-12-26 2020-11-23 Protein-based pharmaceutical composition with neuroprotective, immunomodulating, anti-inflammatory and antimicrobial activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2019000113A CU24626B1 (es) 2019-12-26 2019-12-26 Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana

Publications (2)

Publication Number Publication Date
CU20190113A7 CU20190113A7 (es) 2021-09-07
CU24626B1 true CU24626B1 (es) 2022-11-07

Family

ID=76573804

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000113A CU24626B1 (es) 2019-12-26 2019-12-26 Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana

Country Status (6)

Country Link
EP (1) EP4129318A4 (es)
CN (1) CN115209908A (es)
CA (1) CA3165245A1 (es)
CU (1) CU24626B1 (es)
MX (1) MX2022007991A (es)
WO (1) WO2021129897A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112724233B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-13、制法和其药物组合物与用途
TW202327645A (zh) * 2021-09-02 2023-07-16 美商Ｖａｘｃｙｔｅ公司 佐劑化疫苗組合物之穩定化及其用途
CA3233983A1 (en) * 2021-11-02 2023-05-11 Ole-Jan Iversen (Deceased) Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis
CN116350754A (zh) * 2023-05-16 2023-06-30 昆明理工大学 硫氧还蛋白-1在制备抑制皮质酮生成药物中的应用
JP2025063000A (ja) * 2023-10-03 2025-04-15 緑茵生技股▲ふん▼有限公司 ポリペプチド及びそれを血糖のコントロール及び／又は脂肪を減少するのに用いる用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2958198B2 (ja) 1992-09-28 1999-10-06 日誠マリン工業株式会社 鎮痛用医薬組成物
FR2741076B1 (fr) 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques derives des hormones thymiques, leur utilisation a titre de medicament et compositions les contenant
US6030948A (en) * 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
WO1999062505A2 (en) 1998-06-01 1999-12-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
US20030165492A1 (en) * 2000-06-08 2003-09-04 Alberto Panerai Method of treatment of alzheimer's disease with a protein extractable from mammalian organs
JP4925155B2 (ja) * 2002-06-10 2012-04-25 レドックス・バイオサイエンス株式会社 網膜神経細胞機能回復剤
CN1814276A (zh) 2005-01-31 2006-08-09 宝勒日 胸腺素β10的神经保护作用
US20090291884A1 (en) * 2006-11-02 2009-11-26 Michael Agadjanyan Proteins for use in diagnosing and treating infection and disease
CN101204578A (zh) * 2006-12-20 2008-06-25 干春玉 一种具有调节免疫、抗组织损伤及再生修复作用的胸腺素复合制剂
CA2718774A1 (en) * 2008-03-17 2009-12-17 Regenerx Biopharmaceuticals, Inc. Improved beta thymosin fragments
US20100166789A1 (en) 2008-07-25 2010-07-01 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
WO2010025434A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN101693104A (zh) 2009-10-01 2010-04-14 厦门大学 胸腺5肽的新用途
ES2360333B1 (es) 2009-10-29 2012-05-04 Consejo Superior De Investigaciones Cientificas (Csic) (70%) Derivados de bis (aralquil) amino y sistemas (hetero) aromaticos de seis miembros y su uso en el tratamiento de patologias neurodegenerativas, incluida la enfermedad de alzheimer
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
ES2479815B1 (es) 2012-12-24 2015-05-06 Consejo Superior De Investigaciones Cientificas (Csic) Peptido neuroprotector asi como su uso en el tratamiento de enfermedades cerebrovasculares y otras patologias del snc
KR101745520B1 (ko) * 2015-05-29 2017-06-12 아주대학교산학협력단 신규한 tlr4 길항제
RU2678987C2 (ru) 2017-04-28 2019-02-05 Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" Пептид для лечения болезни альцгеймера
US20190015361A1 (en) 2017-07-17 2019-01-17 Maxwell Biosciences, Inc. Polytherapy modulating cathelicidin gene exprtession modulation for the treatment of alzheimer's disease and other conditions
CN109718363B (zh) 2017-10-26 2019-12-13 拜西欧斯（北京）生物技术有限公司 预防、缓解或治疗阿尔茨海默病的肽及其应用
CU24508B1 (es) 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl

Also Published As

Publication number Publication date
WO2021129897A1 (es) 2021-07-01
EP4129318A4 (en) 2024-05-29
CN115209908A (zh) 2022-10-18
MX2022007991A (es) 2022-07-21
CU20190113A7 (es) 2021-09-07
EP4129318A1 (en) 2023-02-08
CA3165245A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
CU20190113A7 (es) Composición farmacéutica con fines terapéuticos
CL2023003883A1 (es) Restos de administración terapéutica novedosos y usos de estos
PA8582701A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
CO2022015278A2 (es) Células genéticamente modificadas enriquecidas con mitocondrias y usos de estas
EP2228072A4 (en) CANCER VACCINE COMPOSITION
CU24117B1 (es) Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica
CY1115991T1 (el) Φαρμακευτικη ψεκαζομενη συνθεση που περιλαμβανει ενα αναλογο της βιταμινης d προϊον και ενα κορτικοστεροειδες
MX2020008017A (es) Formulaciones de vidrio y usos de las mismas.
UY38625A (es) Compuestos y su uso en el tratamiento del cáncer
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
CY1125216T1 (el) Δομηματα διανομης για διακυτωση και σχετικες μεθοδους
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
MX2021012894A (es) Compuestos ciclicos de fosfato.
ECSP15028696A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
WO2013082535A3 (en) Controlled-release peptide compositions and uses thereof
BR112023018237A2 (pt) Fenalquilaminas e métodos para fabricação e uso das mesmas
CO2022011183A2 (es) Conjugados de proteínas-compuestos antivirales
CL2025000935A1 (es) Compuesto de anillo fusionado y producto farmacéutico que lo contiene.
GT200300155A (es) Polipeptido t20 pegilado
EA202190217A1 (ru) Формы ивосидениба и фармацевтические композиции
AR033666A1 (es) Compuestos polipeptidicos, los procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, el uso de los mismos para la fabricacion de medicamentos y envases comerciales y articulos de fabricacion que comprenden dichos compuestos y dichas composiciones farmaceuticas
AMOL et al. Role of Rasayan churna in outbreak of COVID-19 as preventive and curative aspect
AR115617A1 (es) Composición cosmética para el tratamiento de las fibras de queratina
MX2020005310A (es) Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo.